Prosecution Insights
Last updated: November 20, 2026
Application No. 19/356,512

SYSTEM AND METHOD FOR PHYSICAL ACTIVITY INFORMED DRUG DOSING

Non-Final OA §101§102§103
Filed
Oct 13, 2025
Priority
Feb 13, 2018 — provisional 62/629,849 +1 more
Examiner
EVANS, ASHLEY ELIZABETH
Art Unit
3687
Tech Center
3600 — Transportation & Electronic Commerce
Assignee
University of Virginia Patent Foundation
OA Round
1 (Non-Final)
17%
Grant Probability
At Risk
1-2
OA Rounds
1y 11m
Est. Remaining
54%
With Interview

Examiner Intelligence

Grants only 17% of cases
17%
Career Allowance Rate
11 granted / 65 resolved
-35.1% vs TC avg
Strong +37% interview lift
Without
With
+37.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
29 currently pending
Career history
115
Total Applications
across all art units

Statute-Specific Performance

§101
36.2%
-3.8% vs TC avg
§103
36.4%
-3.6% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
8.7%
-31.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 65 resolved cases

Office Action

§101 §102 §103
DETAILED ACTION Acknowledgements This office action is in response to the claims filed on October 13, 2025. Claims 1-20 are pending Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Interpretation- 112(f) The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. This application includes one or more claim limitations that do not use the word “means,” but are nonetheless being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, because the claim limitation(s) uses a generic placeholder that is coupled with functional language without reciting sufficient structure to perform the recited function and the generic placeholder is not preceded by a structural modifier. Such claim limitation(s) are: “…[…]…a quantifying module configured to …[…]…” in claim 14 and 15 “…[…]… an accumulation module configured to …[…]…” in claim 14 “…[…]… a generation module configured to…[…]…” in claim 14 “…[…]…a dosing module configured to…[…]…” in claim 14 (see [0109] for the construed corresponding structure, material, or acts described in the specification for the recited modules). Because these claim limitation(s) is/are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, it/they is/are being interpreted to cover the corresponding structure described in the specification as performing the claimed function, and equivalents thereof. If applicant does not intend to have these limitation(s) interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, applicant may: (1) amend the claim limitation(s) to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph (e.g., by reciting sufficient structure to perform the claimed function); or (2) present a sufficient showing that the claim limitation(s) recite(s) sufficient structure to perform the claimed function so as to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. Claim Rejection - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-20 are rejected to under 35 U.S.C 101 as not being directed to eligible subject matter the grounds set out in detail below: Independent Claims 1 and 11: Eligibility Step 1 (does the subject matter fall within a statutory category?): Independent claim 1 falls within the statutory category of a method. Independent claim 14 falls within the statutory category of a machine. Eligibility Step 2A-1 (does the claim recite an abstract idea, law of nature, or natural phenomenon?): Independent claims 1 and 14 claimed invention recite an abstract idea as set forth below: The claim elements in the independent claims (claim 1 as representative) which set forth the abstract idea are: A method for optimized control of -implemented medicament therapy, the method comprising: quantifying a physical activity of a patient; calculating an accumulated physical activity based on the quantified physical activity, wherein the accumulated physical activity represents an aggregate of the physical activity over a predetermined period; generating an activity informed medicament bolus by adjusting a functional medicament therapy bolus with a previous activity component, wherein the previous activity component is determined based, at least in part, on the accumulated physical activity; and generating instructions for use by a medicament delivery device to administer the activity informed bolus. which falls within “certain methods of organizing human activity” as it is generating and following instructions to be used to determine when to administer a bolus. See MPEP § 2106.04(a)(2). Eligibility Step 2A-2 (does the claim recite additional elements that integrate the judicial exception into a practical application?): Independent Claims 1 and 14 do not integrate the judicial exception into a practical application. In Claim 1 the additional elements are: a computer Examiner takes the applicable considerations stated in MPEP 2106.04 (d) and analyzes them below in light of the instant applications disclosure and claim elements as a whole. The additional element, (a), is recited executing the abstract idea and is a computer tool or the equivalent which applies the abstract idea as “apply-it” as it is merely as it is merely applying the abstraction with a generic computer (see instant application spec. [0102]-[0103]). Accordingly, this additional element does not integrate the abstract idea into a practical application because it does not impose any meaningful limits on practicing the abstract idea. The claim is directed to an abstract idea. In Claim 14 the additional elements not already recited in independent claim 1 are: a quantifying module an accumulation module a generation module a dosing module Examiner takes the applicable considerations stated in MPEP 2106.04 (d) and analyzes them below in light of the instant applications disclosure and claim elements as a whole. The additional element, (a)-(d), are recited as computer tools or the equivalent which applies the abstract idea as “apply-it” as it is merely applying the abstraction with a generic computer module (see instant application spec. [0109]). Accordingly, these additional element does not integrate the abstract idea into a practical application because they do not impose any meaningful limits on practicing the abstract idea. The claim is directed to an abstract idea. Accordingly, claims 1 and 14 do not integrate the abstract idea into a practical application. Eligibility Step 2B (Does the claim amount to significantly more?): The independent claims 1 and 14 do not include additional elements that are sufficient to amount to significantly more than the judicial exception because as analyzed above in step 2A prong 2 above, these additional elements, whether viewed individually or as an ordered combination, amount to no more than applying the abstract idea thus insufficient to provide “significantly more”. Therefore, the claims do not amount to significantly more and the claims are ineligible. Dependent Claims 2-13 and 15-20: Eligibility Step 1 (does the subject matter fall within a statutory category?): The dependent claims 2-13 falls within the statutory category of method. The dependent claims 15-20 falls within the statutory category of machine. Eligibility Step 2A-1 (does the claim recite an abstract idea, law of nature, or natural phenomenon?): Dependent claims 2-13 and 15-20 claimed invention continue to recite the abstract idea. Dependent claims 2-13 and 15-20 continue to limit the abstract idea in the independent claims by further limiting quantifying the physical activity in claim 2 and 15, further limiting the previous activity in claims 4, 5, 16, and 17, further limiting the activity profile in claims 6 and 7, further limiting the activity factor in claim 8, further limiting the activity on board in claims 9, 10, and 18, further limiting the functional medicament therapy bolus in claims 11, 13, 19, and 20, and further limiting the meal component in claim 12. Thus, inheriting the same abstract idea which falls within “certain methods of organizing human activity” as it is generating and following instructions to be used to determine when to administer a bolus. See MPEP § 2106.04(a)(2). Eligibility Step 2A-2 (does the claim recite additional elements that integrate the judicial exception into a practical application?): Claims 2-13 and 15-20 do not integrate the judicial exception into a practical application. In Claims 2-13 and 15-20 the additional elements are: A heart rate monitor measurement device Examiner takes the applicable considerations stated in MPEP 2106.04 (d) and analyzes them below in light of the instant applications disclosure and claim elements as a whole. The additional element, (a), is recited a tool or the equivalent which applies the abstract idea as “apply-it” as it is merely applying to the abstraction to gather data measure and gather data. Accordingly, the additional element does not integrate the abstract idea into a practical application because it does not impose any meaningful limits on practicing the abstract idea. The claim is directed to an abstract idea. Eligibility Step 2B (Does the claim amount to significantly more?): Dependent claims 2-13 and 15-20 do not include additional elements that are sufficient to amount to significantly more than the judicial exception for the same reasons given in Prong 2A-2. Therefore, the claims do not amount to significantly more and the claims are ineligible. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 2, 3, 4, 5, 8, 11, 12, 13, 14, 15, 16, 17, 19, and 20 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Davis et. al (hereinafter Davis) (US20170220751A1). As per claim 1, Davis teaches: A method for optimized control of a computer-implemented medicament therapy, the method comprising: quantifying a physical activity of a patient; (e.g. intensity) calculating an accumulated physical activity based on the quantified physical activity, (i.e. duration) wherein the accumulated physical activity represents an aggregate of the physical activity over a predetermined period; (i.e. total duration in time with intensity) ([0195] discloses, “Where user-entered data includes exercise, systems and methods according to present principles may allow users to save specific workouts or events to allow patterns in post workout glycemic fluctuations to be analyzed and potentially found, resulting in appropriate automatic or manual therapy modifications to be made by the decision-support application/functionality. For example, users may save workouts such as "Cardio 1", "Cardio 2", "Get Swoll 1", "Get Swoll 2", and so on. Other gradations of exercise may include those pertaining to intensity, e.g., light, medium, hard, duration, e.g., 5 min., 10 min., 15 min., 20 min., 25 min., 30 min., one hour, and so on.” And see table 2 and table 3 / examiner notes the exercise is quantified by a domain such as level e.g. low and an accumulated physical activity is interpreted by examiner as level for some duration e.g. medium intensity for 10 min. see instant specification [0131] and [0119]) generating an activity informed medicament bolus by adjusting a functional medicament therapy bolus (i.e. The system accordingly indicates to her that she should dose a small amount of insulin) with a previous activity component, (i.e. tends to go high during soccer games or low in other workouts i.e. recognized pattern) wherein the previous activity component is determined based, at least in part, on the accumulated physical activity; (i.e. see fig. 11 total time of physical activity utilized in bolus calculator for trend activity) ([0337] discloses, “For example, using the systems and methods informed by the inputs noted above, the users CGM app, employing decision-support application/functionality, determines, in this example, that she is in a "weekend soccer game" state and adjust parameters for therapeutic decision support accordingly. The system accordingly indicates to her that she should dose a small amount of insulin because she is about to play in a soccer game and that she tends to go high during soccer games. The system is also aware that she sometimes goes low in practices and other workouts. In some implementations, systems and methods according to present principles may guess that she is about to play in a soccer game due to a calendar input, a recognized pattern, user input, and so on, and may also be configured to differentiate games from practice. The user may then dose with the recommended amount.” And see [0179] discloses, “For example, case-based reasoning may be employed to determine what happened to the user in other like situations, or what happened to other like users in other like situations. As smart devices become even more computationally capable, much of the machine learning may happen on such devices. However, much of the current processing can happen in the cloud, and such processing may result I significant amounts of machine learning. In other words, the system learns how one element or "affector" X affects the patient, e.g., how anabolic exercise may impact insulin sensitivity. In this example, if a pump action was initiated with the bolus but did not consider the impact of exercise, and then the user were to go for a run, systems and methods according to present principles may detect this sequence of events and notify the user to "expect a drop" or may provide a recommendation such as "you should eat something now".” And see fig. 11) and generating instructions for use by a medicament delivery device to administer the activity informed bolus. (i.e. provided alert with time to dose) ([0119] discloses, “The system 300 may set the required dose, i.e., the dose calculated to be correct at the time of calculation. An audible, visual, or vibratory alert may then be provided on the pen and/or on the CGM device to alert the user when it is time to dose. In a particular implementation, if the user does not dose at the given time, or within a range of time surrounding the given time, e.g., one or two minutes, the system 300 may recalculate the required dose on a periodic basis, e.g., every five minutes, and provide an updated required dose to the mechanical device 136, until insulin is no longer required, or until the patient performs the injection of the insulin.” And see also [0118]) As per claim 2, Davis teaches: The method of claim 1, wherein quantifying the physical activity is based on physical activity data from a measurement device, a time period when the patient is active, and/or a step count over a time period. ([0195] discloses, “Where user-entered data includes exercise, systems and methods according to present principles may allow users to save specific workouts or events to allow patterns in post workout glycemic fluctuations to be analyzed and potentially found, resulting in appropriate automatic or manual therapy modifications to be made by the decision-support application/functionality. For example, users may save workouts such as "Cardio 1", "Cardio 2", "Get Swoll 1", "Get Swoll 2", and so on. Other gradations of exercise may include those pertaining to intensity, e.g., light, medium, hard, duration, e.g., 5 min., 10 min., 15 min., 20 min., 25 min., 30 min., one hour, and so on.” And see table 2 and table 3 / examiner notes the exercise is quantified by a domain such as level e.g. low and an accumulated physical activity is interpreted by examiner as level for some duration e.g. medium intensity for 10 min. see instant specification [0131] and [0119] and examiner notes the claim recites “or” between the series of elements. Per MPEP § 2143.03, Language that suggests or makes a feature or step optional but does not require that feature or step does not limit the scope of a claim under the broadest reasonable claim interpretation. In addition, when a claim requires selection of an element from a list of alternatives, the prior art teaches the element if one of the alternatives is taught by the prior art. See, e.g., Fresenius USA, Inc. v. Baxter Int’l, Inc., 582 F.3d 1288, 1298, 92 USPQ2d 1163, 1171 (Fed. Cir. 2009).) As per claim 3, Davis teaches: The method of claim 2, wherein the measurement device is a heart rate monitor. ([0242] discloses, “Signals may be collected from sensors within smart watches such as the Apple Watch and the Microsoft Band to augment certain entered data, e.g., for hypoglycemia detection. The signals can include heart rate, sympathetic/parasympathetic balance (inferred from heart rate), perspiration, motion, and the like. The signals can be used in addition to the CGM signal.”) As per claim 4, Davis teaches: The method of claim 1, wherein the previous activity component includes a band defining a range of accumulated physical activity levels in which no physical activity related adjustment occurred. ([0333] discloses, “In a more specific example, a user may be about to play an intramural soccer game with her friends. In current practice, she may check her blood glucose and trend, e.g., on her CGM app. She may see that she is in her target range and is steady. The user may desire to know if she should give herself some carbs or some insulin before her soccer game. In the past, she may take a small snack (with an arbitrary or unknown number of carbs) so as to avoid going low during the game. She also desires to not go high, but would rather go higher than low.” / examiner notes the band defining a range in which no physical activity related adjustment occurred is interpreted as trending physical activity as disclosed in which in the e.g. soccer did not apply any special correction or change with the band being the target range) As per claim 5, Davis teaches: The method of claim 1, wherein the previous activity component is further determined based on an activity profile of the patient and/or an activity factor of the patient. ([0168] discloses, “While insulin sensitivity is a useful quantity to profile (and define states for) in a user for diabetes decision support, other useful profiles/states include those corresponding to carbs on board, insulin on board, blood sugar, CGM glucose value, past CGM values on the same kind of day (weekend, weekday) at the same approximate time of day, exercise, exercise on board, and so on. A given parameterized model can be optimized based on values over time and variations determined and quantified of these above states.” / examiner notes activity factor under BRI is interpreted as insulin sensitivity or e.g. carbs on board, exercise on board) As per claim 8, Davis further teaches: The method of claim 5, wherein the activity factor is determined based on an amount of the accumulated physical activity that has the same impact on a glucose level of the patient as a single unit of the medicament. ([0436] discloses, “In some examples, a system may, when confidence in the model is high ( e.g., model parameters have been verified or evaluated for accuracy), use a model to test scenarios and predicted outcomes to assess whether a patient or clinician should consider adjusting treatment parameters, such as insulin-to-carb ratio or insulin sensitivity factor. For example, the system may run a variety of "tests" on the model, which would be burdensome or time consuming for the patient too actually carry out (because of the need to strictly control food, activity, or insulin deliver), and use the results of the tests to determine guidance or a timing of guidance, or to select one or more tests for the patient to actually carry out (e.g., deliver guidance "Your insulin-to carbohydrate ratio may be incorrect: Please conduct a test at your next meal" or "Your basal rate may be incorrect: Please conduct a fasting basal test at your earliest convenience…[…]…In another example, the system may determine, assuming the basal rate is correct, what would happen if a specified amount ( e.g., 1 unit) of insulin were given, and the system may use this information to suggest an update to an insulin sensitivity factor.”) As per claim 11, Davis further teaches: The method of claim 1, wherein the functional medicament therapy bolus is based on a meal component, a correction component, and/or a previous medicament component. ([0455] discloses, “For example, the first real-time datum may indicate a deviation in meal-time, a missed, early, or late insulin dose, a variation in physical activity (e.g. missed workout or atypical workout), or an early or late awakening. In some examples, the behavior model may indicate a tendency to over-correct at a meal associated with a meal time, the first real-time datum indicates that a mealtime is imminent, and the guidance message may correspond to a lessened overcorrection ( e.g. smaller insulin dose or different combination of basal and bolus doses) at the mealtime.”) As per claim 12, Davis further teaches: The method of claim 11, wherein the meal component is based on a ratio of an estimated carbohydrate intake and an amount of carbohydrate compensated by one unit of the medicament. ([0436] discloses, “In some examples, a system may, when confidence in the model is high ( e.g., model parameters have been verified or evaluated for accuracy), use a model to test scenarios and predicted outcomes to assess whether a patient or clinician should consider adjusting treatment parameters, such as insulin-to-carb ratio or insulin sensitivity factor. For example, the system may run a variety of "tests" on the model, which would be burdensome or time consuming for the patient too actually carry out (because of the need to strictly control food, activity, or insulin deliver), and use the results of the tests to determine guidance or a timing of guidance, or to select one or more tests for the patient to actually carry out (e.g., deliver guidance "Your insulin-to carbohydrate ratio may be incorrect: Please conduct a test at your next meal" or "Your basal rate may be incorrect: Please conduct a fasting basal test at your earliest convenience…[…]…In another example, the system may determine, assuming the basal rate is correct, what would happen if a specified amount ( e.g., 1 unit) of insulin were given, and the system may use this information to suggest an update to an insulin sensitivity factor.”) As per claim 13, Davis further teaches: The method of claim 1, wherein the functional medicament therapy bolus is determined based on glucose data, target glucose data, estimated carbohydrate intake, carbohydrate ratio, and/or medicament on board. ([0168] discloses, “While insulin sensitivity is a useful quantity to profile (and define states for) in a user for diabetes decision support, other useful profiles/states include those corresponding to carbs on board, insulin on board, blood sugar, CGM glucose value, past CGM values on the same kind of day (weekend, weekday) at the same approximate time of day, exercise, exercise on board, and so on. A given parameterized model can be optimized based on values over time and variations determined and quantified of these above states.” And see [0299] discloses, “In yet another implementation, the decision-support application/functionality could provide open loop advice on bolus values, as well as recommendations for short term or long-term adjustments to basal insulin. As noted above, dose adjustments may be provided in predefined increments, e.g., 0%, +/-10%, +/-20%, and so on, for ease in administration. While specific examples are given below, here it is noted that an adjustment of a bolus value may be based on, e.g., insulin-on-board, insulin sensitivity, target glucose, current glucose, type of insulin, e.g., long acting versus fast acting, activity after bolus, and so on.) 19. As per claims 14-17 and 19-20, they are system claims which repeat the same limitations of claims 1, 2, 4, 5, 10, 11, and 13 the corresponding method claims, as a collection of elements as opposed to a series of process steps. Since the teachings of Davis disclose the underlying process steps that constitute the methods of claims 1, 2, 4, 5, 10, 11, and 13 it is respectfully submitted that they provide the underlying structural elements that perform the steps as well. As such, the limitations of claims 14-17 and 19-20 are rejected for the same reasons given above for claims 1, 2, 4, 5, 10, 11, and 13 Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 6 is rejected under 35 U.S.C. 103 as being unpatentable over Davis et. al (hereinafter Davis) (US20170220751A1) in view of Steeves et. al (hereinafter Steeves) (Steeves JA, Murphy RA, Crainiceanu CM, Zipunnikov V, Van Domelen DR, Harris TB. Daily Patterns of Physical Activity by Type 2 Diabetes Definition: Comparing Diabetes, Prediabetes, and Participants with Normal Glucose Levels in NHANES 2003-2006. Prev Med Rep. 2015;2:152-157. doi: 10.1016/j.pmedr.2015.02.007. PMID: 25909051; PMCID: PMC4402932.) As per claim 6, Davis does not teach: The method of claim 5, wherein the activity profile is determined based on a median of the accumulated physical activity at a defined time of day over multiple days. However, Steeves does teach: The method of claim 5, wherein the activity profile is determined based on a median of the accumulated physical activity at a defined time of day over multiple days. (see table 3 and see page 154 discloses, “Evaluation of 24 h patterns revealed that PA began between 6:00a.m. and 8:00 a.m.in all groups ,and activity counts per hour increased rapidly in the morning. Median activity counts per hour increased 366% from7:00 to 8:00a.m.,63% from 8:00 to 9:00a.m.,34% from 9:00 to10:00a.m.,and 9% from 10:00to11:00a.m.(Fig.1A).Diabetes participants were significantly less active than those with normal glucose levels from10:00a.m. to 8:00p.m.and significantly less active than the prediabetes participants from10:00 a.m. to 6:00 p.m. (Wilcoxon–Mann Whitney=pb0.00069),with the greatest differences between the groups occurring at4:00p.m. There were no differences between those with normal glucose levels and prediabetes participants (Figs.1A, Band2).” And see methods para. 1 on page 1 disclosing multiple days of data taken) It would be obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine Davis’ teachings as previously cited with Steeves’ teachings as previously cited, the motivation being Davis discloses that detecting and quantifying glucose levels such as low blood sugar in patients executing physical activity in diabetes patients effectively and continuously is still a growing need without too much burden on the patient themselves (see e.g. [0003]-[0007]), thus it would be obvious to one of ordinary skill that Steeves’ teachings of hour by hour activity counts across multiple days with median activity accounted for would improve objective measuring of physical activity and increase accuracy of glucose level quantification reducing overall burden of responsible on a patient to log and determine care needed. Claim 9, 10, and 18 are rejected under 35 U.S.C. 103 as being unpatentable over Davis et. al (hereinafter Davis) (US20170220751A1) in view of Catt et. al (hereinafter Catt) (US10182748B2) As per claim 9, Davis does not teach: The method of claim 1, wherein an activity on board defines the accumulated physical activity. However, Catt does teach: The method of claim 1, wherein an activity on board defines the accumulated physical activity. (see fig. 4 and fig. 6 and see Col. 10 lines 25-36 discloses, step counting in relation to integrated continuous blood glucose and see Col. 12 lines 51-62 which discloses an accumulated activity of step count impulses over a period of time and see Col. 16 lines 13-33 which discloses the relationship between integrated blood glucose and step count in relation to physical clearance rates and these combined results in fig. 4 and 6 give the clearance curve for activity onboard by convolving step count impulses. / examiner notes activity onboard is interpreted as previous cumulative activity such as steps as disclosed used in combination results with glucose monitoring) It would be obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine Davis’ teachings as previously cited with Catt’s teachings as previously cited, the motivation being Davis discloses that detecting and quantifying glucose levels such as low blood sugar in patients executing physical activity in diabetes patients effectively and continuously is still a growing need without too much burden on the patient themselves (see e.g. [0003]-[0007]), thus it would be obvious to one of ordinary skill that Catt’s teachings of continuous glucose monitoring modulated by cumulative physical activity to detect glucose clearance would improve objective measuring of glucose levels and physical activity which can modulate those levels in a patient and increase accuracy of glucose level quantification reducing overall burden of responsibility on a patient to log and determine care needed. As per claim 10, Davis does not teach: The method of claim 9, wherein the activity on board is determined as a weighted sum of physical activity over a time period where the time period and weighting for the physical activity at each time period are obtained from an activity clearance curve. However, Catt does teach: The method of claim 9, wherein the activity on board is determined as a weighted sum of physical activity over a time period where the time period and weighting for the physical activity at each time period are obtained from an activity clearance curve. (see fig. 1 and see Col. 12 lines 51-62 discloses, weighted summation of physical activity over a period of time in relation to glucose clearance and see Col. 10 lines 25-36 discloses, step counting in relation to integrated continuous blood glucose and see Col. 12 lines 51-62 which discloses an accumulated activity of step count impulses over a period of time and see Col. 16 lines 13-33 which discloses the relationship between integrated blood glucose and step count in relation to physical clearance rates and these combined results in fig. 4 and 6 give the clearance curve for activity onboard by convolving step count impulses.) It would be obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to combine Davis’ teachings as previously cited with Catt’s teachings as previously cited, the motivation being the same reasoning given for claim 9. As per claim 18, it is a system claim which repeat the same limitations of claim 10 the corresponding method claim, as a collection of elements as opposed to a series of process steps. Since the teachings of Davis and Catt as well as motivations to combine disclose the underlying process steps that constitute the methods of claim 10 it is respectfully submitted that they provide the underlying structural elements that perform the steps as well. As such, the limitations of claim 18 is rejected for the same reasons given above for claim 10. Prior Art Cited But Not Relied Upon Simpson et. al (hereinafter Simpson) (US20220068452A1) Provided are systems and methods using which users may learn and become familiar with the effects of various aspects of their lifestyle on their health , e.g. , users may learn about how food and / or exercise affects their glucose level and other physiological parameters , as well as overall health . In some cases the user selects a program to try ; in other cases , a computing environment embodying the system suggests programs to try , including on the basis of pattern recognition , i.e. , by the computing environment determining how a user could improve a detected pattern in some way . In this way , users such as type II diabetics or even users who are only prediabetic or non - diabetic may learn healthy habits to benefit their health . Atlas et. al (hereinafter Atlas) (US20120246106A1) a. Monitoring system and method for use with diabetic treatment management. The system includes: a communication interface configured to permit access to stored raw log data, obtained over a certain time, being indicative of glucose measurements, meals consumed and insulin delivery; and a control unit including an unsupervised learning controller con figured to receive and process said raw log data and determine at least one global insulin pump setting of basal rate, correction factor, carbohydrate ratio and insulin activity curve parameters. The system may include a processing unit including a first processor for processing measured data indicative of blood glucose level and generating first processed data, a second processor including at least one fuzzy logic module which receives input parameters corresponding to the measured data, the first processed data and a reference data, and processes the data to produce a qualitative output parameter to determine whether any treatment parameter should be modified. Francescato et. al (hereinafter Francescato) (US20080214905A1) a. A method for estimating the amount of carbohydrates needed by a DP-1 during a specific session of physical activity, com prises the following steps: defining of working constants and standard parameters; introducing of patient and therapy spe cific parameters, calculating of patient specific reference curves for a percentage carbohydrates consumption (% CHO); Scheduling a training session; estimating the amount of carbohydrates (CHO) to be eaten before said physical activity; updating in real time the residual carbohydrates still available during said physical activity; and estimating the amount of carbohydrates to be restored after said physical activity. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ashley Elizabeth Evans whose telephone number is (571) 270-0110. The examiner can normally be reached Monday – Friday 8:00 AM – 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mamon Obeid can be reached on (571) 270-1813. The fax phone number for the organization where this application or proceeding is assigned 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center. Should you have questions on access to the Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /ASHLEY ELIZABETH EVANS/Examiner, Art Unit 3687 /MAMON OBEID/Supervisory Patent Examiner, Art Unit 3687
Read full office action

Prosecution Timeline

Oct 13, 2025
Application Filed
Sep 11, 2026
Non-Final Rejection mailed — §101, §102, §103
Nov 04, 2026
Interview Requested
Nov 12, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12763198
AUTOMATIC SLEEP STAGING CLASSIFICATION WITH CIRCADIAN RHYTHM ADJUSTMENT
4y 5m to grant Granted Oct 13, 2026
Patent 12712072
Adaptive Troubleshooting For A Medical Device
3y 6m to grant Granted Aug 18, 2026
Patent 12700510
SYSTEM AND METHOD FOR IMPROVING PATIENT TREATMENT
2y 4m to grant Granted Aug 04, 2026
Patent 12518860
APPARATUS AND METHOD FOR CALCULATING AN OPTIMUM MEDICATION DOSE
4y 1m to grant Granted Jan 06, 2026
Patent 12505921
PLATFORM FOR ROUTING CLINICAL DATA
3y 4m to grant Granted Dec 23, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
17%
Grant Probability
54%
With Interview (+37.4%)
3y 0m (~1y 11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 65 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month